Does Johnson & Johnson Have a Growth Problem?

This episode of The Motley Fool's Market Checkup is dedicated to the world's largest health-care conglomerate, Johnson & Johnson . Market Checkup gives a full examination of J&J's second-quarter results and takes a closer look at the company's three main business segments: medical devices and diagnostics, pharmaceuticals, and consumer.

In this video, health-care analysts David Williamson and Max Macaluso drill down on medical devices and diagnostics, J&J's largest segment. Watch and find out why the company's reported growth may not be as strong as it appears, and why this division may get a name change in the not too distant future.

One of the best parts of owning Big Pharma stocks is their attractive dividends, but smart investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report "Secure Your Future With 9 Rock-Solid Dividend Stocks" outlines the Fool's favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.

The article Does Johnson & Johnson Have a Growth Problem? originally appeared on

David Williamson owns shares of Pfizer, Johnson & Johnson, Abbott Labs, and AbbVie. Follow David on Twitter: @MotleyDavidMax Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends and owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Can't get enough business news?

Sign up for Finance Report by AOL and get everything from retailer news to the latest IPOs delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.